Content continues after advertisement

Therapeutics Research Note: Pimobendan

Clinician's Brief (Capsule)

Sign in to Print/View PDF

Pimobendan, a phosphodiesterase-III inhibitor and calcium sensitizer, has positive survival benefits in dogs with congestive heart failure from mitral valve degeneration. Initial clinical trials in humans showed a trend toward increased arrhythmias and sudden death but no significant difference in type or incidence of supraventricular or ventricular arrhythmias were seen in this double-blind, randomized, placebo- controlled crossover study of 8 dogs. With 2 weeks of pimobendan treatment, average heart rate and sleeping respiratory rate were lower than baseline values.  


For global readers, a calculator to convert laboratory values, dosages, and other measurements to SI units can be found here.

All Clinician's Brief content is reviewed for accuracy at the time of publication. Previously published content may not reflect recent developments in research and practice.

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.


Clinician's Brief:
The Podcast
Listen as host Alyssa Watson, DVM, talks with the authors of your favorite Clinician’s Brief articles. Dig deeper and explore the conversations behind the content here.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© 2023 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Terms & Conditions | DMCA Copyright | Privacy Policy | Acceptable Use Policy